FROM:
Lancet 1997 (Oct 4); 350 (9083): 990–994
Ingram D, Sanders K, Kolybaba M, Lopez D
University Department of Surgery,
Queen Elizabeth II Medical Centre,
Perth, Western Australia
BACKGROUND: Phyto-oestrogens are a group of naturally
occurring chemicals derived from plants; they have a structure
similar to oestrogen, and form part of our diet. They also have
potentially anticarcinogenic biological activity. We did a
case-control study to assess the association between
phyto-oestrogen intake (as measured by urinary excretion) and the
risk of breast cancer.
METHODS: Women with newly diagnosed early breast cancer
were interviewed by means of questionnaires, and a 72 h urine
collection and blood sample were taken before any treatment
started. Controls were randomly selected from the electoral roll
after matching for age and area of residence. 144 pairs were
included for analysis. The urine samples were assayed for the
isoflavonic phyto-oestrogens daidzein, genistein, and equol, and
the lignans enterodiol, enterolactone, and matairesinol.
FINDINGS: After adjustment for age at menarche, parity,
alcohol intake, and total fat intake, high excretion of both
equol and enterolactone was associated with a substantial
reduction in breast-cancer risk, with significant trends through
the quartiles: equol odds ratios were 1.00, 0.45 (95% Cl 0.20,
1.02), 0.52 (0.23, 1.17), and 0.27 (0.10, 0.69)--trend p =
0.009--and enterolactone odds ratios were 1.00, 0.91 (0.41,
1.98), 0.65 (0.29, 1.44), 0.36 (0.15, 0.86)--trend p = 0.013. For
most other phytoestrogens there was a reduction in risk, but it
did not reach significance. Difficulties with the genistein
assay precluded analysis of that substance.
INTERPRETATION: There is a substantial reduction in
breast-cancer risk among women with a high intake (as measured by
excretion) of phyto-oestrogen, particularly the isoflavonic
phyto-oestrogen equol and the lignan enterolactone. These
findings could be important in the prevention of breast cancer.